Added to YB: 2026-09-16
Pitch date: 2026-09-10
GNFTF [neutral]
Genfit S.A.
-11.11%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally.
Market Cap
EUR 651.3M
Pitch Price
EUR 14.04
Price Target
N/A
Dividend
N/A
EV/EBITDA
-13.55
P/E
-7.55
EV/Sales
9.89
Sector
Biotechnology
Category
growth
Genfit (GNFT France): NIS2+ adds a recurring diagnostics opportunity alongside MASH treatment growth
GNFTF (monitor): Genfit’s NIS2+ could become a recurring MASH diagnostics franchise as treatment adoption increases, with the company estimating a US market above $1.5bn and 7m annual tests by 2033; nearly three-quarters of mature volumes could come from monitoring treated patients. NASHnext is available through Labcorp and has Medicare coverage, but broader reimbursement, routine physician adoption, successful IVD development and broad MASH drug uptake remain unresolved.
Read full article (3 min)